17,322 Shares in Harmony Biosciences Holdings, Inc. $HRMY Bought by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,322 shares of the company’s stock, valued at approximately $631,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HRMY. EverSource Wealth Advisors LLC boosted its stake in Harmony Biosciences by 589.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock worth $28,000 after acquiring an additional 643 shares in the last quarter. Leonteq Securities AG purchased a new position in shares of Harmony Biosciences during the fourth quarter valued at approximately $30,000. Allworth Financial LP lifted its holdings in shares of Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after purchasing an additional 602 shares during the last quarter. Clearstead Advisors LLC boosted its position in shares of Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock worth $44,000 after purchasing an additional 699 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Harmony Biosciences in the 4th quarter worth approximately $47,000. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Stock Up 3.9%

Shares of Harmony Biosciences stock opened at $42.86 on Thursday. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $43.02. The company has a quick ratio of 3.45, a current ratio of 3.48 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $37.31 and its 200 day moving average is $32.89. The company has a market cap of $2.50 billion, a price-to-earnings ratio of 13.92, a price-to-earnings-growth ratio of 0.38 and a beta of 0.93.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, August 4th. The company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.32. The business had revenue of $261.28 million during the quarter, compared to the consensus estimate of $250.77 million. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. The firm’s revenue was up 30.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.92 EPS. Research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.77 EPS for the current year.

Analysts Set New Price Targets

HRMY has been the subject of a number of analyst reports. UBS Group reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Harmony Biosciences in a research report on Wednesday, August 5th. Needham & Company LLC boosted their target price on Harmony Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Wall Street Zen raised Harmony Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 16th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $39.00 price target on shares of Harmony Biosciences in a report on Wednesday, August 5th. Finally, Zacks Research cut shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Five investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $47.11.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.